论文部分内容阅读
多年来,第一、第二代H_1受体拮抗剂被用来缓解由组胺作用于H_1受体而引起的症状。然而,变态反应性炎症远不止组胺的释放及作用的结果。迟发型变态反应中白细胞的浸润被认为是变应性炎症反应的标志。专家研究了第二代H_1受体拮抗剂对肥大细胞脱颗粒作用的体外实验模型和白细胞浸润的体内实验模型。文献显示:一类药物(如仙特明和非索那丁),因不需在体内进一步代谢,其体外模型的研究结果更接近体内的实际情况。迄今为止,在变应性激发试验中以及迟发型变应性炎症反应过程中,仙特明是唯一在体内能减少皮肤、鼻、眼及肺部嗜酸细胞浸润的药物。仙特明可防止患异位性皮炎的敏感儿童发展成哮喘的特点已在新近发表的文献中得到证实。
Over the years, the first and second generation H 1 receptor antagonists were used to alleviate the symptoms caused by histamine action on the H 1 receptor. However, allergic inflammation is far more than the result of histamine release and action. Leukocyte infiltration in late-onset allergy is considered a hallmark of allergic inflammation. Experts studied the second generation H_1 receptor antagonist degranulation of mast cells in vitro experimental model and in vivo experimental model of leukocyte infiltration. Literature shows that: a class of drugs (such as cetrodine and fexofenacin), because they do not need to be further metabolized in the body, the in vitro model of the study results closer to the actual situation in the body. To date, CeTex is the only drug that reduces in vivo skin eosinophilic infiltration in the skin, nose, eyes and lungs during allergic provocation tests as well as delayed-type allergic inflammation. The characteristics of centspim to prevent the development of asthma in susceptible children with atopic dermatitis have been confirmed in recently published literature.